The UAB Neurofibromatosis Clinic is looking to enroll adults with Neurofibromatosis Type 1 (NF1) for a clinical trial targeting cutaneous neurofibromas using the investigational drug called selumetinib. Cutaneous neurofibromas are the benign tumors on or in the skin that are common in adults with NF1. Study participants will take selumetinib by mouth as capsules every 12 hours for 24 cycles (one cycle equals 28 days). This study lasts approximately 2 years, unless significant side-effects develop. You may find more information regarding this clinical trial at www.clinicaltrials.gov study number NCT02839720.
For more study details, a clinical trial fair will take place on Saturday, November 4th from 8:00 a.m. - 12:00 p.m. in the Genetic’s Clinic space in the Kirklin Clinic. There will be an informational group session where the trial details will be provided. Anyone that is interested in the pursuing the trial will complete the consent forms and individually screened in a patient room. The informational session will be free of charge and the evaluation will be billed as standard of care, per protocol standards
For additional study questions, contact:
Ashley Cannon, PhD, MS, CGC (Study Coordinator)
Phone: 205-996-2916
Email: ashleycannon@uabmc.edu